<ul><li> Massachusetts-based AI biotechnology company Transition Bio has raised USD 50 million in a Series A funding round led by Northpond Ventures, with participation from Bristol-Myers Squibb, Taiho Ventures, Magnetic Ventures, and other existing investors. The round follows the company’s seed round in November 2020. </ul>
The proceeds will be directed toward advancing its AI-powered drug discovery platform Condensomics and exploring a variety of therapeutic areas and disease indications.
Founded in 2020, Transition Bio leverages AI, machine learning, and microfluidics to develop novel therapeutics based on biomolecular condensates—organelles inside cells that contribute to diseases. The company’s platform follows a four-tier approach: 1) PhaseScan, which screens and gathers data on condensate modulations; 2) CelPhase for imaging and analytics; 3) PhaseSeq to identify best condensate targets by analyzing its effect on cellular processes; and 4) DeePhase for target prediction and in-silico drug discovery.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.